Carolina Pape-Köhler

Dr. Carolina Pape-Köhler


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2026 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Open access
SKStylianos Kopanos
Stylianos Kopanos
AHAnnika Hoyer
Annika Hoyer
FSFerdinand Valentin Stoye
Ferdinand Valentin Stoye
JFJoachim Feldkamp
Joachim Feldkamp
Sjaak PouwelsSjaak Pouwels
Sjaak Pouwels
CPCarolina Pape-Köhler
Carolina Pape-Köhler
Metabolic dysfunction-associated fatty liver disease (MAFLD) is increasingly common among candidates for metabolic and bariatric surgery, yet clinical thresholds defining when surgery is beneficial or contraindicated remain unclear. This systematic review and meta-analysis synthesized evidence from 29 studies including 71,904 patients with biopsy-confirmed or elastography-confirmed MAFLD undergoing sleeve gastrectomy, Roux-en-Y gastric bypass, or other metabolic procedures. Bariatric surgery was associated with marked hepatic and endocrine improvement, with pooled remission rates of 70% for steatohepatitis, 57% for fibrosis, and 59% for type 2 diabetes. Both sleeve gastrectomy and Roux-en-Y gastric bypass achieved comparable metabolic and hepatic benefits, supporting the role of weight-independent mechanisms such as enhanced incretin signaling and improved insulin sensitivity. Postoperative complications occurred in 15% of patients, including 4% major complications, indicating an overall acceptable safety profile. Across studies, patients with compensated cirrhosis experienced meaningful hepatic improvement, whereas those with decompensated cirrhosis, clinically significant portal hypertension, or impaired hepatic reserve had higher morbidity and limited benefit. Endocrine instability-particularly poorly controlled endocrine disease (e.g., uncontrolled diabetes or untreated thyroid dysfunction)-also emerged as a relative contraindication due to impaired healing and unpredictable metabolic responses. These findings underscore the need for careful preoperative evaluation integrating liver staging, endocrine profiling, and metabolic capacity. Overall, bariatric surgery provides substantial hepatic and endocrine benefits for appropriately selected MAFLD patients, while advanced cirrhosis and uncontrolled endocrine disease represent key thresholds at which surgical risk may outweigh benefit. A multidisciplinary liver-endocrine approach is essential for optimal candidate selection and postoperative outcomes.

2 September 2026 in Obesity Pillars
Verified
Journal Article
Open access
MBMatin Bidares
Matin Bidares
MAMahsa Aziz
Mahsa Aziz
SSSara Samadzadeh
Sara Samadzadeh
RBRamtin Bidares
Ramtin Bidares
Sjaak PouwelsSjaak Pouwels
Sjaak Pouwels
CPCarolina Pape-Köhler
Carolina Pape-Köhler

8 October 2025 in Reports
Verified
Journal Article
Open access
PDF file
CPCarolina Pape-Köhler
Carolina Pape-Köhler
CSChristine Stier
Christine Stier
SKStylianos Kopanos
Stylianos Kopanos
JFJoachim Feldkamp
Joachim Feldkamp
Background and Clinical Significance: Roux-en-Y gastric bypass (RYGB) significantly alters glucose metabolism, yet managing glucose variability in patients undergoing bariatric surgery remains challenging. Continuous Glucose Monitoring (CGM) offers real-time insights into glucose fluctuations and may support long-term metabolic management in this population. This case highlights the utility of CGM in identifying postprandial glycemic variability and guiding dietary adjustments. Case Presentation: A 45-year-old female, 14 years post-RYGB, presented with symptoms including postprandial fatigue, nocturnal cravings, and unexplained weight gain, despite adherence to nutritional guidelines. Her BMI had decreased from 52 kg/m2 (pre-surgery) to 29 kg/m2. She was provided with a CGM device (FreeStyle Libre 3) by the clinical team and instructed to monitor glucose without modifying her routine initially. Data revealed significant glycemic variability, with peaks up to 220 mg/dL and hypoglycemic dips to 45 mg/dL. Based on this, she adjusted her diet by reducing non-complex carbohydrates and increasing vegetables, proteins, and complex carbohydrates. Within two weeks, her symptoms improved, including better sleep and energy levels, accompanied by a 3 kg weight loss following dietary adjustments informed by CGM feedback. Conclusions: This case suggests how CGM can empower patients having undergone bariatric surgery to manage glucose fluctuations through informed self-management. The patient’s ability to identify and address glucose variability without formal intervention highlights CGM’s potential as a supportive tool in long-term care. While further studies are needed, this case suggests CGM may benefit similar patients experiencing postprandial symptoms or weight regain after bariatric surgery.

2 July 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
SKStylianos Kopanos
Stylianos Kopanos
JFJasper David Feldkamp
Jasper David Feldkamp
JTJohanna Tyssen
Johanna Tyssen
XLXinjun Li
Xinjun Li
KSKristina Sundquist
Kristina Sundquist
JFJoachim Feldkamp
Joachim Feldkamp
Objective: Thyroid hormone treatment is the standard therapy for hypothyroidism, particularly in women. Concerns have been raised that exogenous thyroid hormone use may increase breast cancer risk, but evidence remains inconclusive. This study aimed to systematically review and synthesize observational evidence on the association between thyroid hormone treatment and breast cancer risk in women. Design: We conducted a systematic review and meta-analysis of observational studies. Methods: MEDLINE, EMBASE, and Web of Science were searched from January 1976 to February 2025. Eligible studies assessed breast cancer incidence in adult women receiving thyroid hormone treatment versus non-users. Pooled ORs were calculated. Findings from cohort studies reporting hazard ratios were synthesized qualitatively. Heterogeneity, publication bias, and certainty of evidence were assessed. PROSPERO ID: CRD42022348966. Results: Four case–control studies including 221,254 women receiving thyroid hormone treatment and 4,385,666 controls were included in the prespecified primary OR-based meta-analysis. In the primary random-effects meta-analysis, thyroid hormone treatment showed a possible epidemiological signal with breast cancer risk (OR 1.43, 95% CI: 0.90–2.28; I2 = 94.3%), although the confidence interval crossed unity and heterogeneity was substantial. Formal assessment of publication bias was performed but should be interpreted cautiously given the small number of included studies. The certainty of evidence was rated as low due to heterogeneity, serious inconsistency and imprecision. Conclusions: Thyroid hormone treatment was associated with a possible epidemiological signal for breast cancer in observational studies; however, the primary pooled estimate was not statistically significant and should be interpreted as hypothesis-generating because of substantial heterogeneity and residual confounding. Further well-designed prospective studies are required before causal or clinical inferences can be made.

16 April 2026 in Obesity Surgery
Verified
Journal Article
Open access
PDF file
LSLena Seidemann
Lena Seidemann
AHAnnika Hoyer
Annika Hoyer
ADArne Dietrich
Arne Dietrich
Sjaak PouwelsSjaak Pouwels
Sjaak Pouwels
CPCarolina Pape-Köhler
Carolina Pape-Köhler
Background: While seasonal fluctuations in health behaviors such as dieting are well known, little is known about their influence on metabolic bariatric surgery (MBS) consultation timing. This study examines whether the season of first clinical presentation for MBS differs by sex and whether timing impacts early outcomes. Materials and methods: Data from 21,396 patients in the German StuDoQ/MBE registry (2014–2019) were analyzed. Monthly and seasonal presentation probabilities were compared by sex. Logistic regression assessed predictors of early-year consultation. Linear mixed models with random intercepts were used to evaluate the effect on weight loss at 3 and 12 months postoperatively. Results: Presentation patterns differed significantly between sexes. Women presented more frequently in spring and summer, while men showed a clear peak in the first quarter, aligning with calendar-based triggers like New Year’s resolutions. These trends suggest sex-specific motivators: body image awareness in women versus functional limitations and external cues in men. Despite seasonal variation in consultation timing, postoperative weight loss outcomes showed no statistically significant differences across all seasons. Conclusion: The timing of MBS consultation might be influenced by seasonal and sex-specific behavioral patterns. However, outcomes are unaffected by the time of year patients enter treatment. Recognizing these trends can inform tailored patient communication and engagement strategies. Future bariatric programs may benefit from sex-sensitive, seasonally adaptive approaches to optimize patient readiness and long-term success.

21 July 2026
Verified
Book Chapter
Closed access
PDF file
CPCarolina Pape-Köhler
Carolina Pape-Köhler
ATAline Tiegelkamp
Aline Tiegelkamp